No Data
Yiming Enke-B (01541.HK) announced positive clinical trial results for IMM0306 combined with lenalidomide treatment for chronic lymphoma.
Gelonghui, November 18 - Yiming Anke-B (01541.HK) announced that the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has recruited a total of 27 evaluable patients (25 patients with follicular lymphoma (FL) and two patients with marginal zone lymphoma (MZL)) as of October 26, 2024. The following figure illustrates the efficacy data for patients with relapsed or refractory (R/R) FL as of October 26, 2024: as of October 26, 2024, the overall response rate in 25 evaluable R/R FL patients is...
Express News | Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Eli Lilly and Company (01541.HK) has initiated a phase II clinical trial of IMM27M for the treatment of estrogen receptor-positive (ER+) advanced breast cancer that has failed endocrine therapy or recurred.
Kanghui November 13th 丨 Yimingangke-B (01541.HK) announced that the company has initiated Phase II clinical trials for IMM27M therapy for estrogen receptor-positive (ER+) advanced breast cancer after endocrine therapy failure or relapse, and has recruited the first patient. In addition, the IMM27M Phase I dose escalation study was completed at the end of 2023, with the following results (as of August 6, 2024): In the Phase I trial, a total of eight evaluable ER+ advanced or metastatic breast cancer patients were recruited. Among them, two achieved partial response (PR) and four patients had stable disease (SD), overall.
HK Stock Market | Yimingangke-B (01541) opened more than 4% higher, the core product IMM01 III clinical trial completed the first patient dosing.
Yiming Angke-B (01541) opened over 4% higher, as of the time of writing, up 4.19%, priced at 9.7 Hong Kong dollars, with a transaction amount of 3.4551 million Hong Kong dollars.
ImmuneOnco Biopharmaceuticals Doses First Patient in Phase 3 Leukemia Drug Trial
Individual Investors Are ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) Biggest Owners and Were Rewarded After Market Cap Rose by HK$703m Last Week
No Data
No Data